JP2010540547A - アリスキレンおよびバルサルタンのガレヌス製剤 - Google Patents

アリスキレンおよびバルサルタンのガレヌス製剤 Download PDF

Info

Publication number
JP2010540547A
JP2010540547A JP2010527091A JP2010527091A JP2010540547A JP 2010540547 A JP2010540547 A JP 2010540547A JP 2010527091 A JP2010527091 A JP 2010527091A JP 2010527091 A JP2010527091 A JP 2010527091A JP 2010540547 A JP2010540547 A JP 2010540547A
Authority
JP
Japan
Prior art keywords
component
fixed dose
dose combination
pharmaceutical oral
oral fixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010527091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540547A5 (enExample
Inventor
ラルフ・アルテンブルガー
マギー・バビオル・ソニエ
ニコレ・バルゲンダ
ミヒャエラ・アンナ・マリア・ボック
ザビーネ・アドラー
ブルーノ・ブス
カトリーヌ・カルディ
インドラジト・ゴーシュ
シュテファン・ヒルシュ
パトリス・フランソワ・ケレール
ヒャル・コホハル
リ・ショウフェン
ニコレッタ・ロッジャ
アモル・シン・マサル
ジュリアン・テールミト
ウェイ−キン・トン
スダ・ビッパグンタ
ウェン・ホン
マリー−クリスティーヌ・ウォル
ジェイ・パーシバン・ラクシュマン
ジェイムズ・コワルスキー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010540547(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010540547A publication Critical patent/JP2010540547A/ja
Publication of JP2010540547A5 publication Critical patent/JP2010540547A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010527091A 2007-09-28 2008-09-24 アリスキレンおよびバルサルタンのガレヌス製剤 Withdrawn JP2010540547A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97590907P 2007-09-28 2007-09-28
US97591907P 2007-09-28 2007-09-28
US97590107P 2007-09-28 2007-09-28
US97592507P 2007-09-28 2007-09-28
PCT/US2008/077416 WO2009045795A2 (en) 2007-09-28 2008-09-24 Galenical formulations of aliskiren and valsartan

Publications (2)

Publication Number Publication Date
JP2010540547A true JP2010540547A (ja) 2010-12-24
JP2010540547A5 JP2010540547A5 (enExample) 2012-11-01

Family

ID=40377183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527091A Withdrawn JP2010540547A (ja) 2007-09-28 2008-09-24 アリスキレンおよびバルサルタンのガレヌス製剤

Country Status (18)

Country Link
US (1) US20100209480A1 (enExample)
EP (1) EP2205233A2 (enExample)
JP (1) JP2010540547A (enExample)
KR (1) KR20100063090A (enExample)
CN (1) CN101808631A (enExample)
AR (1) AR066168A1 (enExample)
AU (1) AU2008309058B2 (enExample)
BR (1) BRPI0817442A2 (enExample)
CA (1) CA2698330A1 (enExample)
CL (1) CL2008002829A1 (enExample)
CO (1) CO6270217A2 (enExample)
EC (1) ECSP10010052A (enExample)
MA (1) MA31706B1 (enExample)
MX (1) MX2010003441A (enExample)
PE (1) PE20090654A1 (enExample)
TN (1) TN2010000135A1 (enExample)
TW (1) TW200924737A (enExample)
WO (1) WO2009045795A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540489A (ja) * 2007-09-28 2010-12-24 ノバルティス アーゲー 有機化合物のガレヌス製剤
JP2015504878A (ja) * 2011-12-26 2015-02-16 ノバルティス アーゲー 錠剤及び有核剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
MX2011009844A (es) * 2009-03-20 2011-09-29 Novartis Ag Composicion farmaceutica que comprende alisquireno.
CN102348452A (zh) * 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
AR080683A1 (es) * 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2766423A1 (en) * 2011-10-12 2014-08-20 Dow Global Technologies LLC Injection-molded dosage form
CN103349652B (zh) * 2013-05-11 2014-11-19 辽宁大学 含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
EP2248520A3 (en) * 2004-10-08 2010-11-17 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
KR20080000624A (ko) * 2005-04-27 2008-01-02 노파르티스 아게 아테롬성동맥경화증의 치료 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540489A (ja) * 2007-09-28 2010-12-24 ノバルティス アーゲー 有機化合物のガレヌス製剤
JP2015504878A (ja) * 2011-12-26 2015-02-16 ノバルティス アーゲー 錠剤及び有核剤

Also Published As

Publication number Publication date
EP2205233A2 (en) 2010-07-14
CL2008002829A1 (es) 2009-06-26
BRPI0817442A2 (pt) 2015-06-16
MX2010003441A (es) 2010-04-21
CO6270217A2 (es) 2011-04-20
AU2008309058A1 (en) 2009-04-09
WO2009045795A3 (en) 2009-07-16
TN2010000135A1 (en) 2011-09-26
WO2009045795A2 (en) 2009-04-09
TW200924737A (en) 2009-06-16
AU2008309058B2 (en) 2012-08-09
KR20100063090A (ko) 2010-06-10
AR066168A1 (es) 2009-07-29
MA31706B1 (fr) 2010-09-01
PE20090654A1 (es) 2009-06-27
CN101808631A (zh) 2010-08-18
US20100209480A1 (en) 2010-08-19
ECSP10010052A (es) 2010-04-30
CA2698330A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
AU2008309058B2 (en) Galenical formulations of Aliskiren and Valsartan
US20230240994A1 (en) Medicament-containing hollow particle
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
US20120100221A1 (en) Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
JP2009524651A (ja) マルチプルユニット型徐放性経口製剤およびその製造方法
ZA200101485B (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same.
CN1988889A (zh) 含托吡酯的缓释制剂及其制备方法
CN101808665A (zh) 阿利吉仑和缬沙坦的药物组合
WO2019073477A1 (en) PHARMACEUTICAL COMPOSITION OF APREMILAST WITH EXTENDED RELEASE
AU2011288256A1 (en) Oral controlled release pharmaceutical compositions of Blonanserin
US20110177166A1 (en) Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation
JP2015091830A (ja) 有機化合物のガレヌス製剤
TWI745598B (zh) 非布司他控釋組合物及其製備方法
EP1830819A1 (en) Stable pharmaceutical composition comprising amoxicillin and clavulanic acid
HK40049256A (en) Medicament-containing hollow particle
HK40008441A (en) Medicament-containing hollow particle
HK40008438A (en) Medicament-containing hollow particle
JP2012520892A (ja) アリスキレンを含む医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110913

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121109